Perbandingan Nilai Ankle Brachial Index pada Pasien Chronic Myeloid Leukemia yang Mendapatkan Terapi IMATINIB Dan NILOTINIB di Rumah Sakit Umum Pusat Haji Adam Malik

Abstract

Introduction : Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by leukocytosis with immature granulocytics, basophilia, splenomegaly and genetic disorders in pleuripotent stem cells in the form of fusion of the BCR-ABL gene, Philadelphia chromosome [t(9; 22),(Q34; q11.2)]. Treatment with tyrosine kinase inhibitors (TKIs) has been used commonly in CML patients. Tyrosine kinase inhibitors have side effects on the cardiovascular system including occlusion of the arteries. Method : The study was conducted at Haji Adam Malik Hospital using medical record data and Ankle Brachial Index value measurements from December 2023 to February 2024. Observational analytical research design with cross sectional approach to prove the Comparison of Ankle Brachial Index Values in Chronic Myeloid Leukemia Patients Receiving Imatinib and Nilotinib Therapy at the Adam Malik Hospital. The study sample was 48 people who were an affordable population Results : This study was followed by 48 CML patients at the Hematology and Medical Oncology Polyclinic of Haji Adam Malik Hospital. Most of the study subjects were male (30 people). A total of 34 subjects received Imatinib therapy and 14 subjects received Nilotinib. The Imatinib group had an average age of 42.9 years, while the Nilotinib group had an average age of 49.1 years. In the Imatinib group, ABI values included in the Abnormal category were 7 people (20.6). In the Nilotinib group, ABI values included in the Abnormal category were 7 people (50%). Statistically, it is known that there is a difference in ABI values between CML patients and Imatinib or Nilotinib (p = 0.042, Odds Ratio 3.857). Conclusion : This study showed a significant difference in ABI values in CML patients receiving Imatinib and Nilotinib therapy, where the Nilotinib group was more at risk of suffering from PAD.